Integer Holdings Corporation Appoints Michael Coyle to Board of Directors

Michael Coyle joins Integer's Board, bringing over 40 years of medical device leadership and technology experience.

Quiver AI Summary

Integer Holdings Corporation has appointed Michael Coyle to its Board of Directors, bringing over 40 years of leadership experience in the medical device industry. Coyle, who has previously served as president and CEO of iRhythm Technologies and held significant roles at Medtronic, St. Jude Medical, and Eli Lilly, will also be part of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He is currently on the boards of Haemonetics Corporation and BaroPace and holds six U.S. patents related to cardiovascular devices. Pamela Bailey, the Board Chair, highlighted Coyle's skills as valuable for driving growth, while CEO Joseph Dziedzic expressed confidence that Coyle's expertise will enhance Integer's strategy in the medical device manufacturing sector.

Potential Positives

The appointment of Michael Coyle to the Board of Directors adds significant leadership experience from over 40 years in the medical device industry.
Coyle's background includes previous roles as president and CEO of iRhythm Technologies and executive positions at Medtronic, enhancing Integer's credibility and expertise.

Potential Negatives

Appointment of a new board member might suggest prior leadership gaps or challenges in attracting talent.
Potential overreliance on new board member's past experiences from previous companies, which may not align perfectly with Integer's current strategic needs or culture.
Announcement lacks specific details on how Michael Coyle's appointment will directly impact company performance, raising questions about the effectiveness of the new leadership strategy.

FAQ

Who is Michael Coyle?

Michael Coyle is a newly appointed director at Integer Holdings Corporation with over 40 years of leadership experience in the medical device industry.

What committees will Michael Coyle serve on at Integer?

Michael Coyle will serve on the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee at Integer.

What companies did Michael Coyle work for before Integer?

Before Integer, Coyle served as CEO of iRhythm Technologies and held executive roles at Medtronic, St. Jude Medical, and Eli Lilly.

What degrees does Michael Coyle hold?

Coyle holds a master's degree in business administration from the Wharton School and a bachelor's degree from Case Western Reserve University.

How does Integer view its board composition?

Integer regularly evaluates its board composition to ensure it has the necessary skills and perspectives to drive shareholder growth.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$ITGR Insider Trading Activity

$ITGR insiders have traded $ITGR stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.

Here’s a breakdown of recent trading of $ITGR stock by insiders over the last 6 months:

JOSEPH W DZIEDZIC (President & CEO) has made 0 purchases and 3 sales selling 338,975 shares for an estimated $41,751,432.
DONALD J SPENCE sold 14,739 shares for an estimated $1,774,339
MARTIN C MAXWELL has made 0 purchases and 5 sales selling 8,720 shares for an estimated $1,051,278.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$ITGR Hedge Fund Activity

We have seen 154 institutional investors add shares of $ITGR stock to their portfolio, and 159 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

VICTORY CAPITAL MANAGEMENT INC removed 371,225 shares (-72.1%) from their portfolio in Q1 2025, for an estimated $43,808,262
FMR LLC removed 293,215 shares (-31.4%) from their portfolio in Q1 2025, for an estimated $34,602,302
VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. added 282,485 shares (+inf%) to their portfolio in Q1 2025, for an estimated $33,336,054
GOLDMAN SACHS GROUP INC removed 209,201 shares (-34.3%) from their portfolio in Q1 2025, for an estimated $24,687,810
FRANKLIN RESOURCES INC added 209,172 shares (+34.6%) to their portfolio in Q1 2025, for an estimated $24,684,387
POINT72 ASSET MANAGEMENT, L.P. added 199,572 shares (+inf%) to their portfolio in Q1 2025, for an estimated $23,551,491
DRIEHAUS CAPITAL MANAGEMENT LLC removed 187,108 shares (-41.4%) from their portfolio in Q1 2025, for an estimated $22,080,615

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$ITGR Analyst Ratings

Wall Street analysts have issued reports on $ITGR in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Buy" rating on 05/22/2025
Truist Securities issued a "Buy" rating on 04/28/2025
Raymond James issued a "Outperform" rating on 04/25/2025
Benchmark issued a "Buy" rating on 04/25/2025
Keybanc issued a "Overweight" rating on 04/21/2025

To track analyst ratings and price targets for $ITGR, check out Quiver Quantitative's $ITGR forecast page.

$ITGR Price Targets

Multiple analysts have issued price targets for $ITGR recently. We have seen 6 analysts offer price targets for $ITGR in the last 6 months, with a median target of $147.5.

Here are some recent targets:

Joanne Wuensch from Citigroup set a target price of $140.0 on 05/22/2025
Richard Newitter from Truist Securities set a target price of $150.0 on 04/28/2025
Andrew Cooper from Raymond James set a target price of $150.0 on 04/25/2025
Robert Wasserman from Benchmark set a target price of $140.0 on 04/25/2025
Tim Rezvan from Keybanc set a target price of $145.0 on 04/21/2025

Full Release

~ New Director Brings Extensive Medical Device Industry Leadership and Technology Experience to Integer Board ~

PLANO, Texas, July 10, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading global medical device contract development and manufacturing organization (CDMO), today announced it has appointed Michael Coyle to its Board of Directors.

Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee.

He most recently served as president and CEO of iRhythm Technologies, a digital healthcare company. Before that, he was executive vice president and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career.

Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies, Inc. and Volcano Corporation.

He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies.

“Integer’s Board regularly evaluates its composition to ensure it encompasses the appropriate skills, background and perspectives necessary to drive growth for Integer’s shareholders,” said Pamela Bailey, Integer Board Chair. “We are pleased to welcome Michael Coyle, whose extensive medical device industry experience and proven leadership in global business and technology will contribute significantly to our strategic initiatives and culture.”

“The executive leadership team and I look forward to working with Michael as we execute our strategy to deliver sustained outperformance,” said Joseph Dziedzic, Integer president and CEO. “We are confident Michael's expertise will contribute to Integer’s contract development and manufacturing outsourcing strategy, furthering our position as our customers’ partner of choice for innovative medical technologies and services as we realize our vision to enhance the lives of patients worldwide.”

About Integer ^®
Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical ^® and Lake Region Medical ^® . Additional information is available at www.integer.net .

Investor Relations:	Media Relations:
Kristen Stewart	Kelly Butler
[email protected]	[email protected]
551.337.3973	469.731.6617